Company Overview
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 43.6%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $6.50M (+336.9% YoY); net profit $-63.73M.
- Trailing 12 Months Year-on-year growth — revenue +111.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 111.40% |
Stock Price Performance
| 1 Year: | -25.18% |
| 6 Months: | -24.09% |
| 3 Months: | -29.85% |
| 1 Month: | -15.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)36.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 43.6%.
CONS
- Trading 48.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AKTS Aktis Oncology, Inc. R2KR3KPHARMA | 16.76 | -9.86 | $900.79M | 0.00% | -31.96% | 43.61% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 933.00K | 1.45M | 1.87M | 3.23M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 16.57M | 19.59M | 19.25M | 25.93M |
| Operating Income | -15.63M | -18.14M | -17.38M | -22.71M |
| EBITDA | -15.19M | -17.66M | -16.68M | -22.05M |
| Interest Expense | - | - | - | - |
| Pretax Income | -12.06M | -14.98M | -15.14M | -18.32M |
| Tax Provision | - | - | - | - |
| Net Income | -12.06M | -14.98M | -15.14M | -18.32M |
| Diluted EPS | - | -0.43 | - | -0.38 |
| R&D Expense | - | 15.86M | - | 20.04M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.50M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Operating Income | -19.76M | -34.79M | -52.05M | -74.68M |
| EBITDA | -19.32M | -33.60M | -50.48M | -72.36M |
| Interest Expense | - | - | - | - |
| Pretax Income | -17.93M | -28.64M | -43.98M | -63.73M |
| Tax Provision | - | - | - | - |
| Net Income | -17.93M | -28.64M | -43.98M | -63.73M |
| Diluted EPS | -0.51 | -0.82 | -1.26 | -1.21 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 138.32M | 122.36M | 326.18M | 264.88M |
| Current Assets | 132.48M | 100.20M | 300.85M | 230.31M |
| Cash & Equivalents | 128.60M | 29.51M | 37.16M | 37.78M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 157.55M | 168.66M | 413.98M | 411.03M |
| Current Liabilities | 5.28M | 6.24M | 18.82M | 31.24M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.77M | 13.40M | 12.01M | 11.55M |
| Total Equity | -19.23M | -46.31M | -87.80M | -146.15M |
| Shares Outstanding | 52.52M | 52.52M | 52.52M | 52.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -18.12M | -30.00M | 14.76M | -64.13M |
| Investing Cash Flow | -2.31M | -68.83M | -190.40M | 65.96M |
| Financing Cash Flow | 119.98M | 0 | 183.28M | -1.21M |
| Capital Expenditure | -2.31M | -3.76M | -2.86M | -9.58M |
| Free Cash Flow | -20.43M | -33.77M | 11.90M | -73.71M |
| Net Change in Cash | 99.55M | -98.83M | 7.65M | 625.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | -3,500.3% | -1,149.5% |
| Net Margin % | - | - | -2,957.6% | -980.9% |
| ROE % | 93.2% | 61.9% | 50.1% | 43.6% |
| ROCE % | -14.9% | -30.0% | -16.9% | -32.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | MPM Bioimpact LLC | 9.00% | 4.84M | $87.77M |
| 2 | EcoR1 Capital, LLC | 8.98% | 4.82M | $87.56M |
| 3 | Blue Owl Capital Holdings LP | 5.71% | 3.07M | $55.72M |
| 4 | Blackrock Inc. | 4.24% | 2.28M | $41.35M |
| 5 | T. Rowe Price Investment Management, Inc. | 3.82% | 2.05M | $37.23M |
| 6 | Wellington Management Group, LLP | 3.66% | 1.97M | $35.69M |
| 7 | RTW Investments LP | 2.96% | 1.59M | $28.90M |
| 8 | RA Capital Management, L.P. | 2.45% | 1.31M | $23.86M |
| 9 | Jupiter Topco LLC | 2.45% | 1.31M | $23.85M |
| 10 | Baker Bros. Advisors, LP | 1.85% | 996.35K | $18.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AKTS
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castr…
Aktis Oncology to Present at Upcoming September Investor Conferences
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not …
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
Aktis Oncology (AKTS) is well positioned to build a new class of targeted radiation-based cancer dru
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling patients in Phase 1b trial of AKY-1…
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including …
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
What recent performance says about Aktis Oncology Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is down 4.3% over the past month. See our late…
AKTS — Frequently Asked Questions
What is the current share price of Aktis Oncology, Inc. (AKTS)?
As of 2026-10-22 16:30 PDT, Aktis Oncology, Inc. (AKTS) trades at $16.76 on NasdaqGS. Its 52-week range is $15.06 to $32.23.
What is the market capitalisation of AKTS?
Aktis Oncology, Inc. (AKTS) has a market capitalisation of $900.79M on NasdaqGS.
What is the P/E ratio of AKTS?
AKTS trades at a trailing price-to-earnings (P/E) ratio of -9.86. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 2.07.
What is the return on equity (ROE) of AKTS?
AKTS has a return on equity (ROE) of 43.61%. Its return on capital employed (ROCE) is -31.96%.
Is AKTS a good stock to buy?
This page provides a data-driven analysis of Aktis Oncology, Inc. (AKTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.